{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:12:19Z","timestamp":1793146339590,"version":"4.5.0"},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00292-025-01496-w","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:02:22Z","timestamp":1763132542000},"page":"6-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["NECTIN4-Amplifikation als pr\u00e4diktiver Biomarker f\u00fcr das Ansprechen auf Enfortumab-Vedotin","NECTIN4 amplification as a\u00a0predictive biomarker for enfortumab vedotin response"],"prefix":"10.1007","volume":"47","author":[{"given":"Markus","family":"Eckstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"10","key":"1496_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T et\u00a0al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N\u00a0Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"issue":"20","key":"1496_CR2","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","volume":"42","author":"N Klumper","year":"2024","unstructured":"Klumper\u00a0N et\u00a0al (2024) NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. J\u00a0Clin Oncol 42(20):2446\u20132455","journal-title":"J Clin Oncol"},{"issue":"8","key":"1496_CR3","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","volume":"29","author":"N Klumper","year":"2023","unstructured":"Klumper\u00a0N et\u00a0al (2023) Membranous NECTIN\u20114 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clin Cancer Res 29(8):1496\u20131505","journal-title":"Clin Cancer Res"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01496-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-025-01496-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01496-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:57:11Z","timestamp":1768816631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-025-01496-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":3,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1496"],"URL":"https:\/\/doi.org\/10.1007\/s00292-025-01496-w","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Eckstein erkl\u00e4rt folgende potenzielle Interessenskonflikte: Er erhielt Honorare von AstraZeneca, Roche, Astellas, Genomic Health, Janssen, Owkin, Diaceutics, Ferring, Eisai, Merck, BicycleTx, Zytomed Systems und Lilly; Berater- bzw. Gutachtert\u00e4tigkeiten f\u00fcr AstraZeneca, Janssen, Genomic Health, Diaceutics, Gilead Sciences, Owkin, MSD Oncology, Merck, BicycleTx, Lilly und Ferring; Vortragst\u00e4tigkeiten f\u00fcr Diaceutics, Roche, AstraZeneca, MSD, Astellas, Merck, BicycleTx, Zytomed Systems, Eisai, BMS und Regeneron; Forschungsf\u00f6rderung von STRATIFYER, Janssen\/Johnson & Johnson, AstraZeneca\/MedImmune, Owkin, Gilead Sciences, BicycleTx, QuiP GmbH und Cepheid; Reisekostenerstattungen bzw. Unterst\u00fctzung f\u00fcr Teilnahme an wissenschaftlichen Veranstaltungen durch AstraZeneca, Roche, MSD, Janssen-Cilag, Genomic Health, Diaceutics, Astellas Pharma, Ferring, Eisai, Merck, BicycleTx, Cepheid und BMS; Aktienoptionen bei BicycleTx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}